X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5459) 5459
Book Review (1177) 1177
Publication (439) 439
Newsletter (104) 104
Newspaper Article (71) 71
Magazine Article (33) 33
Book Chapter (31) 31
Reference (29) 29
Conference Proceeding (21) 21
Book / eBook (10) 10
Government Document (4) 4
Dissertation (2) 2
Streaming Video (2) 2
Data Set (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
Transcript (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4553) 4553
humans (4346) 4346
thalidomide (3051) 3051
male (2504) 2504
female (2362) 2362
thalidomide - administration & dosage (2172) 2172
middle aged (1935) 1935
aged (1760) 1760
oncology (1736) 1736
thalidomide - analogs & derivatives (1690) 1690
thalidomide - therapeutic use (1649) 1649
multiple myeloma - drug therapy (1642) 1642
hematology (1545) 1545
multiple myeloma (1447) 1447
adult (1386) 1386
antineoplastic combined chemotherapy protocols - therapeutic use (1302) 1302
treatment outcome (1283) 1283
thalidomide - adverse effects (1164) 1164
bortezomib (1092) 1092
lenalidomide (994) 994
therapy (875) 875
animals (855) 855
dexamethasone - administration & dosage (828) 828
care and treatment (720) 720
dexamethasone (720) 720
chemotherapy (705) 705
aged, 80 and over (692) 692
cancer (674) 674
antineoplastic agents - therapeutic use (606) 606
stem-cell transplantation (597) 597
drug therapy (584) 584
pharmacology & pharmacy (562) 562
antineoplastic combined chemotherapy protocols - adverse effects (536) 536
thalidomide - pharmacology (525) 525
survival (507) 507
abridged index medicus (479) 479
multiple myeloma - mortality (478) 478
research (469) 469
medicine & public health (459) 459
dosage and administration (450) 450
disease-free survival (446) 446
multiple-myeloma (428) 428
recurrence (428) 428
boronic acids - administration & dosage (412) 412
multiple myeloma - therapy (411) 411
pyrazines - administration & dosage (411) 411
multiple myeloma - pathology (410) 410
antineoplastic combined chemotherapy protocols - administration & dosage (405) 405
transplantation (400) 400
mice (389) 389
angiogenesis (369) 369
dose-response relationship, drug (368) 368
prognosis (360) 360
angiogenesis inhibitors - therapeutic use (354) 354
trial (349) 349
analysis (347) 347
retrospective studies (346) 346
antineoplastic agents - administration & dosage (345) 345
health aspects (344) 344
drug administration schedule (336) 336
survival analysis (322) 322
follow-up studies (321) 321
drug therapy, combination (316) 316
remission induction (314) 314
risk factors (310) 310
combination (308) 308
immunosuppressive agents - therapeutic use (305) 305
hematology, oncology and palliative medicine (298) 298
survival rate (295) 295
antineoplastic agents - adverse effects (291) 291
melphalan (291) 291
transplantation, autologous (285) 285
plus dexamethasone (279) 279
angiogenesis inhibitors - administration & dosage (272) 272
melphalan - administration & dosage (272) 272
clinical trials (268) 268
clinical trials as topic (268) 268
immunology (262) 262
combined modality therapy (261) 261
disease progression (260) 260
administration, oral (258) 258
multiple myeloma - diagnosis (253) 253
stem cells (253) 253
medicine, general & internal (250) 250
cyclophosphamide - administration & dosage (247) 247
necrosis-factor-alpha (246) 246
multiple myeloma - complications (245) 245
time factors (243) 243
prednisone (242) 242
rats (241) 241
dermatology (239) 239
efficacy (238) 238
diagnosis (233) 233
myeloma (233) 233
elderly-patients (232) 232
immunologic factors - therapeutic use (224) 224
immunosuppressive agents - administration & dosage (224) 224
stem cell transplantation (219) 219
patient outcomes (215) 215
pregnancy (212) 212
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (5) 5
Robarts - Stacks (3) 3
UTL at Downsview - May be requested (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
Online Resources - Online (1) 1
St. Augustine's Seminary - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5440) 5440
Japanese (87) 87
French (57) 57
German (49) 49
Chinese (35) 35
Spanish (23) 23
Czech (14) 14
Polish (8) 8
Italian (7) 7
Dutch (5) 5
Hungarian (4) 4
Portuguese (4) 4
Danish (3) 3
Korean (3) 3
Russian (3) 3
Norwegian (2) 2
Ukrainian (2) 2
Finnish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Experimental Neurology, ISSN 0014-4886, 2009, Volume 220, Issue 1, pp. 191 - 197
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which is currently untreatable. Inflammation plays a major role in the pathogenesis of... 
G93A | Inflammation | Lenalidomide | TNF-α | FasL | SOD1 | ACTIVATION | TNF-alpha | ALS | NECROSIS-FACTOR-ALPHA | THALIDOMIDE | NEUROSCIENCES | MOTOR-NEURON DEGENERATION | SPINAL-CORDS | SUPEROXIDE-DISMUTASE | EXPRESSION | PROGRESSION | Spinal Cord - drug effects | Humans | Body Weight - drug effects | Antineoplastic Agents - therapeutic use | Lameness, Animal - prevention & control | Thalidomide - pharmacology | Amyotrophic Lateral Sclerosis - drug therapy | Body Weight - immunology | Motor Neurons - pathology | Thalidomide - analogs & derivatives | Nerve Degeneration - prevention & control | Anti-Inflammatory Agents - therapeutic use | Antineoplastic Agents - pharmacology | Lameness, Animal - drug therapy | Motor Neurons - drug effects | Disease Models, Animal | Amyotrophic Lateral Sclerosis - immunology | Cell Survival - drug effects | Cytokines - metabolism | Motor Neurons - immunology | Anti-Inflammatory Agents - pharmacology | Mice, Transgenic | Nerve Degeneration - immunology | Survival Rate | Treatment Outcome | Cell Survival - immunology | Lameness, Animal - physiopathology | Spinal Cord - immunology | Animals | Cytokines - drug effects | Amyotrophic Lateral Sclerosis - metabolism | Mice | Spinal Cord - physiopathology | Thalidomide - therapeutic use | Immunologic Factors - pharmacology | Nerve Degeneration - drug therapy | Immunologic Factors - therapeutic use | Medical colleges | Amyotrophic lateral sclerosis | Neurosciences | Angiogenesis inhibitors | RNA | Analysis | Index Medicus
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2009, Volume 15, Issue 6, pp. 718 - 723
Lenalidomide is an agent that has shown great activity in patients with multiple myeloma (MM). However, studies have suggested that this drug negatively... 
Hematology, Oncology and Palliative Medicine | Myeloma | Stem cell mobilization | Autotransplant | COMBINATION THERAPY | NEWLY-DIAGNOSED MYELOMA | PHASE-2 | THALIDOMIDE | BORTEZOMIB | IMMUNOLOGY | CHEMOTHERAPY | TRANSPLANTATION | PLUS DEXAMETHASONE | REFRACTORY MYELOMA | HEMATOLOGY | MELPHALAN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hematopoietic Stem Cell Mobilization - methods | Humans | Middle Aged | Heterocyclic Compounds - pharmacology | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Recombinant Proteins | Filgrastim | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - administration & dosage | Multiple Myeloma - drug therapy | Granulocyte Colony-Stimulating Factor - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Treatment Failure | Angiogenesis Inhibitors - therapeutic use | Vincristine - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacology | Retrospective Studies | Angiogenesis Inhibitors - adverse effects | Multiple Myeloma - surgery | Bone Marrow - drug effects | Doxorubicin - administration & dosage | Multiple Myeloma - blood | Thalidomide - adverse effects | Ifosfamide - pharmacology | Dexamethasone - administration & dosage | Heterocyclic Compounds - administration & dosage | Risk Factors | Etoposide - pharmacology | Etoposide - administration & dosage | Combined Modality Therapy | Thalidomide - administration & dosage | Granulocyte Colony-Stimulating Factor - pharmacology | Leukapheresis | Ifosfamide - administration & dosage | Cyclophosphamide - pharmacology | Aged | Multiple Myeloma - radiotherapy | Thalidomide - therapeutic use | Peripheral Blood Stem Cell Transplantation | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Care and treatment | Granulocyte colony-stimulating factor | Analysis | Multiple myeloma | Stem cells | Transplantation | Angiogenesis inhibitors | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 934 - 941
Journal Article
Blood, ISSN 0006-4971, 07/2012, Volume 120, Issue 1, pp. 9 - 19
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2007, Volume 138, Issue 2, pp. 176 - 185
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 3, pp. 251 - 257
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 800 - 807
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article